{
    "title": "EXPLAINER-Who is eligible for the new FDA-approved Alzheimer's drug?",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12272911/EXPLAINER-Who-eligible-new-FDA-approved-Alzheimers-drug.html",
    "date": "2023-07-06",
    "keywords": [
        "drug",
        "leqembi",
        "approval",
        "brain",
        "fda",
        "risk",
        "coverage",
        "health",
        "label",
        "gene",
        "medicare",
        "beasley",
        "disease",
        "leqembis",
        "agency",
        "eisai",
        "cost",
        "study",
        "outofpocket",
        "reporting",
        "july",
        "food",
        "administration",
        "thursday",
        "decision",
        "plan",
        "antibody",
        "toxic",
        "protein",
        "beta",
        "infusion",
        "trial",
        "rate",
        "decline",
        "placebo",
        "impairment",
        "stage",
        "apoe4",
        "swelling",
        "warning",
        "testing",
        "population",
        "copy",
        "institute",
        "number",
        "market",
        "association",
        "price",
        "year",
        "treatment",
        "database",
        "registry",
        "jama",
        "medicine",
        "state",
        "insurance",
        "medicaid",
        "nothing",
        "support",
        "payment",
        "deena",
        "julie",
        "steenhuysen",
        "chicago",
        "editing",
        "matthew",
        "lewis"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}